- Rapid, profound and durable responses across multiple dosing groups with favorable safety profile observed—positioning barzolimab as a potential best-in-class addition to a historically limited treatment landscape -
- At week 12, 56% of all patients in the 1.5 mg/kg, 3.0 mg/kg and 4.5 mg/kg dose groups had complete response and 76% had well-controlled disease (UAS7/UCT) -
- At week 24, 53% of all patients in the 1.5 mg/kg and 3.0 mg/kg dose groups had complete response and 70% experienced well-controlled disease (UAS7/UCT); additional follow up ongoing in 4.5 mg/kg dose -
- 37% of treated patients had prior omalizumab therapy and still had similar clinical benefit improvement as the overall population -
- Company to host webcast on Sunday, February 26 at 4:00 pm CT/5:00 pm ET -
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
Feb 26, 2023
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers